- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05650866
Seguridad y tolerabilidad de un nuevo dispositivo implantable para el tratamiento de la disfunción eréctil
Seguridad y tolerabilidad de un nuevo dispositivo implantable para el tratamiento de la disfunción eréctil después de una prostatectomía radical
The goal of this clinical trial is to assess if a new device is safe to use as a potential treatment for erectile dysfunction following radical prostatectomy.
The main questions it aims to answer are:
- Is the device safe?
- Does the device works well? Are the participants satisfied with the device?
Participants will be implanted with the device during the ongoing prostatectomy surgery and will be asked to complete the following tasks during 6 months follow-up:
- Come to the hospital for follow-up visits,
- Complete questionnaires,
- Activate the device every day,
- Measure erection hardness.
Researchers will compare an implanted group (participants having the device) with a control group (participants not having the device) to see if the device works well.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Victoria
-
Fitzroy, Victoria, Australia, 3065
- St. Vincent's Private Hospital
-
Melbourne, Victoria, Australia, 3050
- Royal Melbourne Hospital
-
North Melbourne, Victoria, Australia, 3051
- Australian Prostate Centre
-
Richmond, Victoria, Australia, 3121
- Epworth HealthCare
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Men of ages between 30-70 years;
- Men with indication for nerve-sparing prostatectomy surgery;
- Localised prostate cancer considered suitable for bilateral nerve sparing prostatectomy according to clinical criteria
- International Index of Erectile Function (IIEF-15) erectile function domain score equal to or greater than 26 prior prostatectomy;
- Men interested in minimizing the effect of radical prostatectomy on erectile function;
- Ability to read and understand patient information materials and willingness to sign a written informed consent.
Exclusion Criteria:
- Men with neurological disease, including a history of spinal cord injury or trauma;
- IIEF-15 erectile function domain score less than 26 prior prostatectomy;
- Failure to demonstrate adequate nocturnal erectile function prior prostatectomy;
- History of erectile dysfunction, priapism and Peyronie disease;
- History of previous pelvic surgery, trauma or irradiation therapy;
- Currently have an active implantable device;
- Patient diagnosed with neurologic degenerative diseases that may negatively impact erectile functions;
- Identification of technical or clinical limitation to properly apply the use of nerve-sparing techniques during operation;
- Inability to understand and demonstrate device use instructions;
- Patients with insulin-dependent diabetes who suffer peripheral neuropathy or other diabetes associated complications;
- Patient unwillingness to engage in sexual activity;
- Patient is currently participating in another clinical investigation that would serve as a contraindication to implant a neurostimulator device to augment erectile function;
- Have participated in any drug or device trial in the last 4 weeks or plan to participate in any other drug or device study during the next 24 months;
- Possess any other characteristics that, per the investigator's judgment, may increase the risk or impair data collection for the procedure/study;
- Patient is a member of a vulnerable population (Vulnerable participants include those who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, and employee volunteers).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Implanted group
The study device will be implanted during the ongoing prostatectomy surgery. Participants will then be asked to activate it everyday. |
The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function. |
|
Sin intervención: Control group
Participants in the control group will undergo standard prostatectomy and will not be implanted with the study device. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Occurrence of adverse events
Periodo de tiempo: 6 months
|
Adverse events will be reported using MedDRA terminology. |
6 months
|
|
Occurrence of surgical complications
Periodo de tiempo: 6 months
|
Surgical complications will be ranked according to the Clavien-Dindo classification |
6 months
|
|
Occurrence of device deficiencies
Periodo de tiempo: 6 months
|
Device deficiencies will be systematically reported and recorded. |
6 months
|
|
Pain
Periodo de tiempo: 6 months
|
Patients will be asked to rate pain on a visual analog scale (from 0 to 10) |
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective Device effectiveness
Periodo de tiempo: 6 months
|
Erectile response obtained when activating the study device will be objectively assessed by measuring penile rigidity with the RigiScan device. |
6 months
|
|
Subjective Device effectiveness
Periodo de tiempo: 6 months
|
Erectile function will be subjectively assessed by asking participants to complete validated questionnaires (International Index of Erectile Function, IIEF-15 and Erection Hardness Score, EHS). |
6 months
|
|
Erectile function recovery
Periodo de tiempo: 6 months
|
Nocturnal penile erections will be assessed with the RigiScan device. Nocturnal erections reflect the extent of recovery of natural erectile function. |
6 months
|
|
Delineation of the surgical implantation procedure
Periodo de tiempo: 6 months
|
The surgeon will record information related to the implantation (duration, position of the device, grading ease of implantation steps, and any comments). |
6 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- CP-1.5400
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .